MaxCyte delivered a consensus-beating 30% uplift in full-year 2019 (FY19) revenues to US$21.6mln underpinned by the release of milestone payments from its commercial partners as programmes advanced through clinical studies, and by a 25% five-year revenue compound annualised growth rate (CAGR). Ther
28 Apr 2020
MaxCyte: Milestones a key contributor to 30% top line growth
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
MaxCyte: Milestones a key contributor to 30% top line growth
MaxCyte, Inc. (MXCT:LON) | 313 0 0.0% | Mkt Cap: 325.9m
- Published:
28 Apr 2020 -
Author:
Emma Ulker -
Pages:
5
MaxCyte delivered a consensus-beating 30% uplift in full-year 2019 (FY19) revenues to US$21.6mln underpinned by the release of milestone payments from its commercial partners as programmes advanced through clinical studies, and by a 25% five-year revenue compound annualised growth rate (CAGR). Ther